Gefitinib‐induced autologous antitumor immunity

摘要: Aim:  We previously reported that thromboxane (TX) B2, p-selectin, and the cytokine is regulated on activation, normal T expressed secreted (RANTES) were elevated in patients with non-small cell lung cancer (NSCLC) treated gefitinib. It macrophages are activated by platelets. hypothesized medicated gefitinib, we measured their plasma macrophage inflammatory protein (MIP)-1 beta. Methods:  Patients NSCLC not curable surgery entered study received gefitinib at a dose of 250 mg/day over period two weeks. Blood samples drawn before after administration MIP-1 beta was enzyme-linked immunosorbent assay. Results:  A total 28 patients, 42–82-years age (median, 67); 16 men 12 women, subjects study: 21 had adenocarcinomas seven squamous cancers. Partial response to occurred 11 stable disease five progressive disease. The mean serum level evaluable increased significantly medication for 1 2 weeks from baseline 101 ± 19 pg/mL 139 ± 25 pg/mL one week (P < 0.05) 131 ± 29 pg/mL (P < 0.05). Conclusion:  Immunological markers related platelets including as well A2 p-selectin RANTES, undergoing therapy speculate has potential autologous immunological anti-tumor activity.